Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SCMP > SEC Filings for SCMP > Form 8-K on 8-Aug-2013All Recent SEC Filings

Show all filings for SUCAMPO PHARMACEUTICALS, INC.

Form 8-K for SUCAMPO PHARMACEUTICALS, INC.


8-Aug-2013

Results of Operations and Financial Condition, Change in Directors


Item 2.02 Results of Operations and Financial Condition

On August 8, 2013, Sucampo Pharmaceuticals, Inc. ("the Company") announced its consolidated financial results for the quarter ended June 30, 2013. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The slides from the presentation will be referenced below are incorporated by reference.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 5.02 Departure of directors or Certain Officers; Election of directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Departure of directors or Certain Officers On August 2, 2013, Dr. Ryuji Ueno, the Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of the Company advised the Board of Directors of the Company (the "Board") of his decision to focus exclusively on his role as Chief Scientific Officer of the Company and not continue as Chief Executive Officer and Chairman of the Board once a new chief executive officer is named by the Board. His current employment agreement with the Company will remain in effect. The Board expects that Dr. Ueno's successor will be named before the end of the year and will determine at the appropriate time whether or not to appoint another member to the Board after Dr. Ueno leaves the Board.

(e) Compensatory Arrangements of Certain Officers While serving as Chief Scientific Officer, Dr. Ueno will continue to receive his current annual salary and the same level of health insurance and other welfare benefits as he currently receives.



Item 7.01. Regulation FD Disclosure.

On August 8, 2013, the Company will host a conference call with investors to discuss the Company's financial and operating results for the quarter ended June 30, 2013. The conference call including slides will be made available to the public via conference call and webcast. The slides from the presentation are being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibits 99.2 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 8.01 Other Events.

On August 8, 2013, the Company issued a press release announcing the Board's decision to begin a search for a successor to Dr. Ueno as Chief Executive Officer and the decision for Dr. Ueno not to continue as Chairman of the Board and Chief Executive Officer once his successor as Chief Executive Officer is named by the Board. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.3 to this Current Report on Form 8-K.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1      Press Release issued by the Company on August 8, 2013.
99.2      The corporate update presentation slides dated August 8, 2013.
99.3      Press Release issued by the Company on August 8, 2013.


  Add SCMP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SCMP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.